Multiple Sclerosis News TodayAtara to Extend Phase 1 Trial of Potential Immunotherapy for All MS Forms to US PatientsMultiple Sclerosis News TodayATA188 is a T-cell immunotherapy that targets immune B-cells and plasma cells in the brain and spinal cord… Continue reading
|
Drugmakers see a pricing blueprint in an $850000 gene therapy
Reuters SAN FRANCISCO (Reuters) – Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. Spark Therapeutics Inc plans to launch its … |
Xconomy |
Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More
Xconomy Have you gotten your flu shot yet this year? This winter’s flu season is shaping up to be a particularly nasty one and the Centers for Disease Control and Prevention this week upped its tally of states reporting widespread flu activity to 46. Flu … |
|
How can CRISPR genome editing shape the future of cancer research?
Cancer Research UK (blog) We’ve already covered some of the common questions around CRISPR, and how it’s showing promise in immunotherapy. This post takes a look at what CRISPR can offer the future of cancer research. The genome editing technology CRISPR is causing plenty of … |